Cited by 154Diabetes Management and ResearchHyperglycemia and glycemic control in critically ill and hospitalized patientsDiabetes Treatment and Management

Reducing inpatient hypoglycemia in the general wards using real-time continuous glucose monitoring: The glucose telemetry system, a randomized clinical trial

Open access
Singh, Lakshmi G., Satyarengga, Medha, Marcano, Isabel, Scott, William H., Pinault, Lillian F., Feng, Zhaoyong, Sorkin, John D., Umpierrez, Guillermo E. +1 more·2020·Diabetes Care

Abstract

OBJECTIVE: Use of real-time continuous glucose monitoring (RT-CGM) systems in the inpatient setting is considered investigational. The objective of this study was to evaluate whether RT-CGM, using the glucose telemetry system (GTS), can prevent hypoglycemia in the general wards. RESEARCH DESIGN AND METHODS: In a randomized clinical trial, insulin-treated patients with type 2 diabetes at high risk for hypoglycemia were recruited. Participants were randomized to RT-CGM/GTS or point-of-care (POC) blood glucose testing. The primary outcome was difference in inpatient hypoglycemia. RESULTS: Seventy-two participants were included in this interim analysis, 36 in the RT-CGM/GTS group and 36 in the POC group. The RT-CGM/GTS group experienced fewer hypoglycemic events (<70 mg/dL) per patient (0.67 [95% CI 0.34–1.30] vs. 1.69 [1.11–2.58], P = 0.024), fewer clinically significant hypoglycemic events (<54 mg/dL) per patient (0.08 [0.03–0.26] vs. 0.75 [0.51–1.09], P = 0.003), and a lower percentage of time spent below range <70 mg/dL (0.40% [0.18–0.92%] vs. 1.88% [1.26–2.81%], P = 0.002) and <54 mg/dL (0.05% [0.01–0.43%] vs. 0.82% [0.47–1.43%], P = 0.017) compared with the POC group. No differences in nocturnal hypoglycemia, time in range 70–180 mg/dL, and time above range >180–250 mg/dL and >250 mg/dL were found between the groups. The RT-CGM/GTS group had no prolonged hypoglycemia compared with 0.20 episodes <54 mg/dL and 0.40 episodes <70 mg/dL per patient in the POC group. CONCLUSIONS: RT-CGM/GTS can decrease hypoglycemia among hospitalized high-risk insulin-treated patients with type 2 diabetes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc20-0840

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Recent evidence suggests that adding GLP-1 RAs at discharge for selected patients with uncontrolled T2D may improve glycemic control, reduce hypoglycemia, and cause weight loss compared with adding basal insulin.

    “Recent evidence suggests that adding GLP-1 RAs at discharge to select persons with uncontrolled T2D may result in better glycemic control, less hypoglycemia, and weight loss compared with adding basal insulin.1381”

    From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1381]

    The Study Procedures describe basal–bolus insulin during hospitalization, and the Conclusions attribute reduced inpatient hypoglycemia to real-time glucose monitoring and a prevention protocol. A search for GLP-1 receptor agonists at discharge and for weight-loss outcomes found no comparison with adding basal insulin; the Results mention GLP-1 receptor agonists only as part of some participants’ treatment before admission. No passage addresses the claimed discharge-treatment benefits. (LLM, conf=0.76)

    Experimental — accuracy not yet measured
  • Studies assessing effectiveness of inpatient CGM may ultimately lead to approved use of CGM for monitoring hospitalized individuals.

    “Studies have been published assessing the effectiveness of this approach, which may ultimately lead to the approved use of CGM for monitoring hospitalized individuals (277,286-295).”

    From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [294]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Singh, L. G., Satyarengga, M., Marcano, I., Scott, W. H., Pinault, L. F., Feng, Z., Sorkin, J. D., Umpierrez, G. E., & Spanakis, E. K.
Affiliations
  • Baltimore VA Medical Center (US)
  • Center for Diabetes and Endocrinology, University of Maryland Shore Regional Health, Easton, MD
  • University of Maryland, Baltimore (US)
  • Emory University (US)
Corresponding author
Spanakis, Elias K.
Venue
Diabetes Care
Published
2020-08-05
Volume
43
Issue
11
Pages
2736-2743
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W3047317123
Cited by
154
References
35
Citations by year
2026: 18 · 2025: 24 · 2024: 31 · 2023: 19 · 2022: 26 · 2021: 27 · 2020: 9
FWCI
15.27
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Veterans Affairs Clinical Sciences Research and Development Service (VA MERIT award (#1I01CX001825))
  • VA Medical Center GRECC
  • National Institute on Aging
  • National Institute of Diabetes and Digestive and Kidney Diseases (DK-072488)
  • National Institutes of Health (UL1-TR-002378, P30-DK-111024)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
real-time continuous glucose monitoring, type 2 diabetes, insulin-treated patients, nocturnal hypoglycemia, time in range, hospitalized patients, hypoglycemia prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review